Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prostate specific antigen in benign prostatic hyperplasia: purification and characterization

Z Chen1, H Chen, T A Stamey

  • 1Department of Urology, Stanford University School of Medicine, California 94305-5118, USA.

The Journal of Urology
|June 1, 1997
PubMed
Summary

Prostate specific antigen (PSA) in benign prostatic hyperplasia (BPH) nodules is mostly a nicked form with low activity. This explains the higher free-to-total PSA ratio in BPH, aiding in differentiating it from prostate cancer.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Adrenocorticotropic hormone-secreting pheochromocytomas: the exception to the rule.

Surgery·1995
Same author

The mouse obese gene. Genomic organization, promoter activity, and activation by CCAAT/enhancer-binding protein alpha.

The Journal of biological chemistry·1995
Same author

Circadian variation in coronary tone in patients with stable angina. Protective role of the endothelium.

Circulation·1995
Same author

Purification of a heteromeric CCAAT binding protein from Neurospora crassa.

Molecular & general genetics : MGG·1995
Same author

Requirement for neuregulin receptor erbB2 in neural and cardiac development.

Nature·1995
Same author

Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins.

Proceedings of the National Academy of Sciences of the United States of America·1995

Area of Science:

  • Biochemistry
  • Urology
  • Molecular Biology

Background:

  • The ratio of free-to-total prostate specific antigen (PSA) helps differentiate benign prostatic hyperplasia (BPH) from prostate cancer.
  • Understanding the molecular basis of this ratio difference is crucial for improved diagnostics.

Purpose of the Study:

  • To investigate the molecular characteristics of PSA in BPH nodules.
  • To elucidate the reasons for the higher free-to-total PSA ratio observed in BPH compared to prostate cancer.

Main Methods:

  • Purification of PSA from BPH nodule fluids using gel filtration and ion exchange chromatography.
  • Characterization of purified BPH PSA via gel electrophoresis, enzyme assays, and N-terminal sequence analysis.

Main Results:

Related Experiment Videos

  • BPH PSA exists primarily as a 30 kDa nicked form, unlike intact seminal fluid PSA.
  • BPH PSA exhibits multiple internal cleavages and significantly lower chymotrypsin-like activity compared to seminal fluid PSA.
  • N-terminal sequencing revealed BPH PSA is not in its precursor or mature forms, indicating post-translational modification.

Conclusions:

  • Most PSA in BPH nodules is a modified, 'nicked' form with reduced enzymatic activity.
  • This nicked form contributes to a higher free PSA level in circulation, distinguishing BPH from prostate cancer.
  • Proteases within BPH nodules likely cause this modification, suggesting potential diagnostic targets.